Society of Hematologic Oncology Annual Meeting (SOHO)

Jason Westin, MD, discusses patient responses with relapsed/refractory diffuse large B-cell lymphoma in the JULIET trial who were treated with tisagenlecleucel.

Ching-Hon Pui, MD, discusses the use of CAR T-cell therapy in patients with relapsed/refractory acute lymphocytic leukemia.

Tisagenlecleucel maintained strong rates of response and duration of response in adults with relapsed/refractory diffuse large B-cell lymphoma, according to the latest findings from the phase II JULIET study presented at the 2019 SOHO Annual Meeting.

John F. DiPersio, MD, PhD, discusses the challenges in research surrounding targeted cellular therapies for acute myeloid leukemia

The use of checkpoint inhibitors prior to haploidentical stem cell transplantation improved progression-free survival and reduced the risk for relapse for patients with relapsed or refractory Hodgkin lymphoma, according to results from a retrospective study presented at the 2019 SOHO Annual Meeting.

David G. Maloney, MD, PhD, discusses the initiative to use the Center for International Blood and Marrow Transplant Research Cellular Therapy Registry to report real world experience of tisagenlecleucel CAR T cells targeting CD19 in patients with acute lymphoblastic leukemia.

Ruben Mesa, MD, discusses the JAKARTA and JAKARTA-2 studies and the implications their data have on the field of myelofibrosis.

Laura C. Michaelis, MD, discusses the integration of fedratinib into the treatment sequence of myelofibrosis.

Partow Kebriaei, MD, discusses the eligibility criteria necessary for patients with acute lymphocytic leukemia to undergo stem cell transplantation.

Novel strategies are needed to enhance the efficacy of CAR T-cell therapies in patients with acute lymphoblastic leukemia, including new constructs that target more than 1 antigen.

Reducing or interrupting duvelisib treatment does not increase toxicity or reduce outcomes with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Furthermore, treatment with the PI3K inhibitor led to a superior median progression-free survival compared with ofatumumab while producing rapid and durable responses in heavily pretreated patients.